Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Is it in here somewhere

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 02, 2022 1:46pm

150 Views

Post# 34648246

RE:Is it in here somewhere

No - not on the IBD side.

It's on the "wound healing" side.
CITA membranes and bone products may have found their future more on the gaseous mediator side where cell health, pain, inflammation - could all be leveraged to speed up wound healing.

So, when I saw this wheel, I was very happy to see that selling CITA wouldn't cause us to give up this direction (in general) - maybe we gave it up specifically in bone/membrane products but that's less strategic going forward.

IMO

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions